{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = (8R,9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-2,3,4,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol
| image = Cingestol.svg
| width =

<!--Clinical data-->
| tradename = Lutisan
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = [[Oral administration|Oral]]

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 16915-71-2
| CAS_supplemental = 
| ATC_prefix = 
| ATC_suffix = 
| PubChem = 11954351
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 10128646
| UNII = VLJ9702J11

<!--Chemical data-->
| C=20 | H=28 | O=1
| molecular_weight = 284.43572 g/mol
| smiles = C[C@]12CC[C@H]3[C@@H](CC=C4CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
| StdInChI_Ref = 
| StdInChI = 1S/C20H28O/c1-3-20(21)13-11-18-17-9-8-14-6-4-5-7-15(14)16(17)10-12-19(18,20)2/h1,8,15-18,21H,4-7,9-13H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1
| StdInChIKey_Ref = 
| StdInChIKey = HSYWFJBHXIUUCZ-XGXHKTLJSA-N
| synonyms = <small>19-Nor-17α-pregn-5-en-20-yn-17β-ol</small>; O.V. 28<ref name="Tausk1975">{{cite book|author=M. Tausk|title=Pharmacology of hormones|url=https://books.google.com/books?id=9WhNAQAAIAAJ|year=1975|publisher=Thieme|isbn=978-3-13-518901-7|page=126,129}}</ref><ref>{{cite book|title=Concours médical|url=https://books.google.com/books?id=_UQgAQAAMAAJ|year=1976|page=1083}}</ref>
}}

'''Cingestol''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]]) (former tentative brand name '''Lutisan'''),<ref>{{cite book|title=Registry of Toxic Effects of Chemical Substances|url=https://books.google.com/books?id=dRFV2ZV6DT0C|year=1987|publisher=National Institute for Occupational Safety and Health|page=2995}}</ref> also known as '''17α-ethynylestr-5-en-17β-ol''',<ref name="Brotherton1976">{{cite book|author=Janet Brotherton|title=Sex hormone pharmacology|url=https://books.google.com/books?id=zt5sAAAAMAAJ|year=1976|publisher=Academic Press|isbn=978-0-12-137250-7|page=12}}</ref> is a [[steroid]]al [[progestin]] of the [[19-nortestosterone]] group<ref name="Korolkovas1988">{{cite book|author=Andrejus Korolkovas|title=Essentials of Medicinal Chemistry|url=https://books.google.com/books?id=6hxtAAAAMAAJ|date=16 August 1988|publisher=Wiley|isbn=978-0-471-88356-2}}</ref><ref>{{cite book|title=WHO Technical Report Series|url=https://books.google.com/books?id=WlQYAAAAMAAJ|year=1981|publisher=World Health Organization|page=75}}</ref> that was never marketed.<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA279|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=279–}}</ref> It was synthesized in 1969<ref name="Elks2014" /> and was developed in the 1970s by [[Organon International|Organon]] as a low-dose, [[progestogen-only pill|progestogen-only]] [[hormonal contraceptive|contraceptive]],<ref name="Tapingkae1974">{{cite book|author=Amnuay Tapingkae|title=Directory of selected scholars and researchers in Southeast Asia|url=https://books.google.com/books?id=mB4gAQAAMAAJ|year=1974|publisher=Regional Institute of Higher Education and Development|page=687}}</ref><ref name="BriggsBriggs1976">{{cite book|author1=Michael H. Briggs|author2=Maxine Briggs|title=Biochemical contraception: prospects for human development|url=https://books.google.com/books?id=7pRsAAAAMAAJ|year=1976|publisher=Academic Press|isbn=978-0-12-134640-9|page=283}}</ref><ref name="pmid4124151">{{cite journal | vauthors = Aref I, Hefnawi F, Kandil O, Aziz MT | title = Effect of minipills on physiologic responses of human cervical mucus, endometrium, and ovary | journal = Fertil. Steril. | volume = 24 | issue = 8 | pages = 578–83 | year = 1973 | pmid = 4124151 | doi = 10.1016/s0015-0282(16)39850-8| url = http://www.popline.org/node/492373}}</ref><ref name="pmid4375129">{{cite journal | vauthors = Kićović PM, Kovacević S, Djokic LJ, Milojević S, Janoskov J, Behlilović B, Jeremić N | title = Clinical evaluation of a new low dose progestagen-only contraceptive containing cingestol | journal = Int. J. Fertil. | volume = 19 | issue = 3 | pages = 171–5 | year = 1974 | pmid = 4375129 | doi = | url = http://www.popline.org/node/494146}}</ref> but in 1984, was still described as "under investigation".<ref name="CuttingCsáky1984">{{cite book|author1=Windsor Cooper Cutting|author2=T. Z. Csáky|author3=Byron A. Barnes|title=Cutting's Handbook of Pharmacology: The Actions and Uses of Drugs|url=https://books.google.com/books?id=B-1sAAAAMAAJ|year=1984|publisher=Appleton-Century-Crofts|isbn=978-0-8385-1418-4|page=439}}</ref> The drug is an [[isomer]] of [[lynestrenol]] with the double bond between C5 and C6.<ref name="Tausk1975" />

==See also==
* [[Allylestrenol]]

==References==
{{reflist|30em}}

{{Progesterone receptor modulators}}

[[Category:Estranes]]
[[Category:Progestogens]]


{{genito-urinary-drug-stub}}
{{steroid-stub}}